OptiDose Technology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

OptiDose Technology

Catalent’s OSDrC® OptiDose™ enables design of dividable, multi-layer, single or multi-core tablets with a practically endless variety of core numbers, shapes, sizes, and placement. The flexible-core capability provides new alternatives in controlled release designs for drug formulators, developers, and marketers in a high quality, one step manufacturing processes.  This expands tableting capabilities in many areas that differentiate beyond existing technologies.

OptiDose technology provides the flexibility to design single or multiple API in a single tablet, with different release profiles.  In addition to shown improvement in mass variability between layers, OptiDose also offers tablet design to minimize cross-layer interaction of API and improved product stability.

One of the more recognized approaches for developing high quality controlled release formulations, Wurster fluid bed technology is a bottom-spray approach, where a coating medium is sprayed onto the particle. Compared to alternative technologies, it produces a more consistent coating for powders, granules, pellets, and micro-tablets, with higher quality controlled release product due to more predictable residence time within the coating zone.

Catalent recently invested in major capacity expansions at its Schorndorf, Germany; Somerset, NJ; and Winchester, KY, facilities to increase fluid bed capacity and capabilities to meet growing customer demand.

Company name:  Catalent Pharma Solutions
Website: www.catalent.com
E-mail: info@catalent.com

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
FindPharma Custom Search

Click here